Rallybio Corp (RLYB)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$16.93+0.30%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · RLYB
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -72.1% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Worth watching into the next print: this name has been missing across recent quarters and is a smaller-cap name (higher miss base rate). A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
RLYB — M&A activity — Changes in Control of Registrant
Dated 2026-06-01
Changes in Control of Registrant. To the extent required by this Item, the information included in
Why it matters: The earnings report will provide updates on financial health and future plans. Investors will look for signs of improvement in revenue and loss-making status.
Watch forRallybio shares its next earnings date. It also gives positive revenue guidance.
Also watch forEarnings date is announced with continued loss-making status and no revenue growth.
Why it matters: Data readouts will show how well RLYB116 is performing in clinical trials. Positive results could boost investor confidence.
Supportive ifManagement confirms data readouts for RLYB116 study cohorts are on track for Q3 2025.
Worry ifManagement is delaying the data readouts for RLYB116. This is later than expected.
Why it matters: Rallybio needs to manage its losses well. Better cost management can help improve finances.
Supportive ifOperating losses fell more from negative $5.7 million in 2026-Q2.
Worry ifOperating losses increase or fail to improve from current levels.
Why it matters: Cutting operating losses is important for financial health. Progress shows better cost control.
Supportive ifOperating income improves to less than negative $8.7M in the next quarter.
Worry ifOperating losses worsen beyond negative $8.7M in the next quarter.
Why it matters: Positive data from AVZO-021 could increase trust in the new oncology pipeline. This is important for the future of the combined company.
Supportive ifNew safety and efficacy results from the Phase 1 study will be shown at ASCO 2026.
Worry ifData shows no clinical activity. There are also no safety issues in the Phase 1 study.
Why it matters: Earnings results will show how well the company is doing financially.
Watch forThe earnings report shows smaller losses than in past quarters.
Also watch forThe earnings report shows bigger losses or does not meet what was expected.
Why it matters: If healthcare sector revenue growth speeds up, it could benefit Rallybio. A stronger sector can improve investor sentiment.
Supportive ifHealthcare sector revenue growth speeds up toward 10% or more.
Worry ifHealthcare sector revenue growth keeps slowing down below current levels.
Why it matters: Losing more money could show that cost management is still a problem.
Worry ifQ2 operating losses reported worse than -$8.73M.
Less concerning ifOperating losses improve or stay below -$8.73M.
Why it matters: The merger is a key growth step for Rallybio. It will create a new company focused on oncology therapies.
Supportive ifThe merger will close as planned in Q4 2026. Stockholder approvals are secured.
Worry ifThe merger fails to close by Q4 2026 due to stockholder or regulatory issues.
Why it matters: Progress on RLYB116 is crucial for Rallybio's growth in treating rare diseases.
Supportive ifNew positive updates come from the RLYB116 clinical study.
Worry ifNo updates or negative results from the RLYB116 study are reported.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$81 on $10,000 · ±0.8% | How much price usually moves either way. |
| Bad day | $516 loss on $10,000 · 5.2% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $3,105 loss on $10,000 · 31.1% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.